SAFETY, PHARMACOKINETICS, AND IMMUNOLOGICAL EFFECTS OF OMILANCOR (BT-11) IN A PHASE 2 RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF PATIENTS WITH ULCERATIVE COLITIS

Josep Bassaganya-Riera  ¹     Andrew Leber     Nuria Tubau-Juni     Jyoti Chauhan     Jean-Frédéric Colombel  ²     Simon Lichtiger     Raquel Hontecillas    
¹ Landos Biopharma, Inc., Blacksburg, United States
² Icahn School of Medicine at Mount Sinai, New York, United States

Topic
IBD, Immunology

Session
IBD: Clinical trials III

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)